Insights

Innovative Cancer Therapy Platform TransCode Therapeutics has developed a proprietary delivery platform, TTX, that targets microRNA-10b, a master regulator in metastatic cancer cells. This advanced platform offers significant opportunities for collaborations or licensing deals with pharmaceutical companies seeking to enhance their targeted cancer therapies.

Strong Clinical Progress The company's recent Phase 1a clinical trial successfully achieved its primary safety endpoint and established a recommended Phase 2 dose, indicating promising early efficacy. This positioning provides an opening to engage investors or partners interested in supporting further clinical development and commercialization.

Expansion & Strategic Acquisitions TransCode's acquisition of Polynoma LLC and substantial investment from CK Life Sciences demonstrate strategic growth and validation. This expansion signals potential opportunities for technology partnership, joint development programs, or research collaborations to accelerate product pipeline advancement.

Leadership & Expert Network Recent high-profile hires, including a new CEO and senior scientific advisory members, strengthen the company's leadership and technical expertise. This presents opportunities to collaborate with their expert network or explore consultant arrangements to co-develop novel therapeutic solutions.

Financial Growth & Market Activity With revenues in the 1-10 million dollar range, ongoing funding, and recent industry recognition, TransCode is positioned for future expansion. There are potential sales opportunities with biotechnology and pharma firms looking for innovative oncology assets or investment in emerging cancer therapeutics.

Similar companies to TransCode Therapeutics, Inc.

TransCode Therapeutics, Inc. Tech Stack

TransCode Therapeutics, Inc. uses 8 technology products and services including Google Fonts API, Mustache, jQuery, and more. Explore TransCode Therapeutics, Inc.'s tech stack below.

  • Google Fonts API
    Font Scripts
  • Mustache
    Javascript Frameworks
  • jQuery
    Javascript Libraries
  • ScrollReveal
    Javascript Libraries
  • reCAPTCHA
    Security
  • Cloudflare Bot Management
    Security
  • Adobe Fonts
    Web Fonts
  • Apache
    Web Servers

Media & News

TransCode Therapeutics, Inc.'s Email Address Formats

TransCode Therapeutics, Inc. uses at least 1 format(s):
TransCode Therapeutics, Inc. Email FormatsExamplePercentage
First.Last@transcodetherapeutics.comJohn.Doe@transcodetherapeutics.com
48%
Last@transcodetherapeutics.comDoe@transcodetherapeutics.com
3%
Last.F@transcodetherapeutics.comDoe.J@transcodetherapeutics.com
1%
First.Last@transcodetherapeutics.comJohn.Doe@transcodetherapeutics.com
48%

Frequently Asked Questions

What is TransCode Therapeutics, Inc.'s official website and social media links?

Minus sign iconPlus sign icon
TransCode Therapeutics, Inc.'s official website is transcodetherapeutics.com and has social profiles on LinkedInCrunchbase.

What is TransCode Therapeutics, Inc.'s SIC code NAICS code?

Minus sign iconPlus sign icon
TransCode Therapeutics, Inc.'s SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does TransCode Therapeutics, Inc. have currently?

Minus sign iconPlus sign icon
As of December 2025, TransCode Therapeutics, Inc. has approximately 15 employees across 2 continents, including North AmericaEurope. Key team members include Chief Executive Officer: Q. L.Ceo & Chairman, Transcode Therapeutics (nasdaq: Rnaz): P. C.Chief Technology Officer: Z. M.. Explore TransCode Therapeutics, Inc.'s employee directory with LeadIQ.

What industry does TransCode Therapeutics, Inc. belong to?

Minus sign iconPlus sign icon
TransCode Therapeutics, Inc. operates in the Biotechnology Research industry.

What technology does TransCode Therapeutics, Inc. use?

Minus sign iconPlus sign icon
TransCode Therapeutics, Inc.'s tech stack includes Google Fonts APIMustachejQueryScrollRevealreCAPTCHACloudflare Bot ManagementAdobe FontsApache.

What is TransCode Therapeutics, Inc.'s email format?

Minus sign iconPlus sign icon
TransCode Therapeutics, Inc.'s email format typically follows the pattern of First.Last@transcodetherapeutics.com. Find more TransCode Therapeutics, Inc. email formats with LeadIQ.

How much funding has TransCode Therapeutics, Inc. raised to date?

Minus sign iconPlus sign icon
As of December 2025, TransCode Therapeutics, Inc. has raised $10M in funding. The last funding round occurred on Mar 23, 2025 for $10M.

When was TransCode Therapeutics, Inc. founded?

Minus sign iconPlus sign icon
TransCode Therapeutics, Inc. was founded in 2016.

TransCode Therapeutics, Inc.

Biotechnology ResearchMassachusetts, United States11-50 Employees

TransCode's goal is delivering a cancer-free future for all cancer patients. Our core belief is that cancer can be overcome through the intelligent design and efficient delivery of targeted therapeutics. Our lead therapeutic candidate, TTX-MC138, targets microRNA-10b, or miRNA-10b, considered the master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and several others. 

TransCode believes it has overcome this barrier, opening the door to a broad array of cancer therapies -- a disease with the highest unmet need that affects everyone. It is through the design and optimization of this technology that TransCode has devised an elegant solution -- TTX -- a proprietary delivery platform for the transport of targeted therapeutics to cancer cells. With their world class team and know how, TransCode has a rapidly expanding platform of drug candidates designed to target a variety of tumor indications with the goal of long-term treatment survival.

Important Notice: Recruitment Fraud Alert
We are aware of recruitment scams in which fraudsters pose as representatives of TransCode Therapeutics to deceive job seekers. Please note the following to protect yourself:
    •    We NEVER ask for payment or personal financial information during the recruitment process.
    •    All legitimate communication from our team will come from an official @transcodetherapeutics.com email address 
    •    Our hiring process always includes formal interviews—either virtual or in-person.
    •    If you receive a  job offer claiming to be from us, please do NOT respond. Report it to info@transcodetherapeutics.com.

Section iconCompany Overview

SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2016
Employees
11-50

Section iconFunding & Financials

  • $10M

    TransCode Therapeutics, Inc. has raised a total of $10M of funding over 15 rounds. Their latest funding round was raised on Mar 23, 2025 in the amount of $10M.

  • $1M$10M

    TransCode Therapeutics, Inc.'s revenue is estimated to be in the range of $1M$10M

Section iconFunding & Financials

  • $10M

    TransCode Therapeutics, Inc. has raised a total of $10M of funding over 15 rounds. Their latest funding round was raised on Mar 23, 2025 in the amount of $10M.

  • $1M$10M

    TransCode Therapeutics, Inc.'s revenue is estimated to be in the range of $1M$10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.